Anzeige
Mehr »
Montag, 29.09.2025 - Börsentäglich über 12.000 News
Seltene Ausgangslage: Unbekannter Kupfer-Explorer mit spekulativem Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W7Q9 | ISIN: BE0974260896 | Ticker-Symbol: 1C0
Frankfurt
29.09.25 | 08:14
0,280 Euro
+0,72 % +0,002
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CELYAD ONCOLOGY SA Chart 1 Jahr
5-Tage-Chart
CELYAD ONCOLOGY SA 5-Tage-Chart
RealtimeGeldBriefZeit
0,2580,33822:48

Aktuelle News zur CELYAD ONCOLOGY Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18:36Celyad Oncology SA: Celyad Oncology Announces Research Facility Divestiture153Regulatory News: Celyad Oncology (Euronext: CYAD) (the "Company"), today announces the divestment of the Company's research facility. Under the terms of an asset purchase agreement, the Company...
► Artikel lesen
FrCelyad Oncology SA GAAP EPS of -$0.093
DoCelyad Oncology SA: Celyad Oncology Reports First Half Year 2025 Financial Results331Regulatory News: Celyad Oncology (Euronext: CYAD) (the "Company"), today announced its financial results for the first half year 2025 ended June 30, 2025. First Half 2025 financial review As...
► Artikel lesen
11.09.Celyad Oncology SA: Publication of a Transparency Notification Received From Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)253Regulatory News: Celyad Oncology SA (Euronext: CYAD) ("Celyad Oncology" or the "Company") today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication...
► Artikel lesen
04.09.Celyad Oncology SA: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)286Regulatory News: Celyad Oncology (Euronext: CYAD) ("Celyad" or the "Company"), today announced that 3,849,040 registered shares benefit from a double voting right as of September 4, 2025. As a...
► Artikel lesen
26.08.Celyad Oncology SA: Celyad Oncology Announces Discontinuation of R&D Activities223Regulatory News: Celyad Oncology (Euronext: CYAD) ("Celyad" or the "Company"), today announced that it has decided to discontinue its research and development (R&D) activities and to implement...
► Artikel lesen
13.08.Celyad Oncology SA: Publication of a Transparency Notification Received from Fortress Investment Group LLC296(Article 14 §1 of the Law of 2 May 2007) Regulatory News: Celyad Oncology SA (Euronext: CYAD) ("Celyad Oncology" or the "Company") today announces, in accordance with Article 14 of the Belgian...
► Artikel lesen
07.08.Celyad Oncology SA: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)476Regulatory News: Celyad Oncology (Euronext: CYAD) (the "Company" or "Celyad Oncology"), today announces the below information following the issuance, on August 5, 2025, of 3,333,333 new shares...
► Artikel lesen
CELYAD ONCOLOGY Aktie jetzt für 0€ handeln
30.07.XFRA 1C0: WIEDERAUFNAHME/RESUMPTION228FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
28.07.Celyad Oncology SA: Celyad Oncology Announces €1 Million Private Placement323Regulatory News: Celyad Oncology (Euronext: CYAD) (the "Company" or "Celyad") today announced that it has entered into a subscription agreement for a private placement financing. Under the terms...
► Artikel lesen
28.07.XFRA 1C0: AUSSETZUNG/SUSPENSION281DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCELYAD ONCOLOGY...
► Artikel lesen
24.06.Celyad Oncology SA: Celyad Oncology Announces Strategic Review354Regulatory News: Celyad Oncology (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (the "Company" or "Celyad") today announced that it is conducting a comprehensive review of strategic alternatives....
► Artikel lesen
02.04.Celyad Oncology SA GAAP EPS of -€0.14, revenue of €0.2M1
02.04.Celyad Oncology Reports Full Year 2024 Financial Results and Recent Business Highlights506Regulatory News: Celyad Oncology (Euronext: CYAD) (the "Company"), today announces its financial results for the fiscal year ended December 31, 2024, and provides a business update. Matt Kane...
► Artikel lesen
18.02.Celyad Oncology SA: Celyad Oncology announces the publication of the preclinical and clinical data of CYAD-211 providing proof-of-concept of its miRNA-based shRNA platform575Regulatory News: Celyad Oncology (Euronext: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (the "Company"), today announces the publication of the preclinical data of the non-gene edited allogeneic...
► Artikel lesen
07.10.24Celyad Oncology SA: Celyad Oncology to Present at the 2024 SITC Annual Meeting556Regulatory News: Celyad Oncology (Euronext: CYAD) (the "Company"), today announces two poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held...
► Artikel lesen
16 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1